Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 13.24 Million USD | 214.28% |
| 2022 | 4.21 Million USD | -78.41% |
| 2021 | 19.52 Million USD | 37.59% |
| 2020 | 14.18 Million USD | 244.94% |
| 2019 | 4.11 Million USD | 40.97% |
| 2018 | 2.91 Million USD | 39.7% |
| 2017 | 2.08 Million USD | 11.78% |
| 2016 | 1.86 Million USD | -60.72% |
| 2015 | 4.75 Million USD | -9.99% |
| 2014 | 5.28 Million USD | 89.47% |
| 2013 | 2.78 Million USD | 6.54% |
| 2012 | 2.61 Million USD | -6.17% |
| 2011 | 2.79 Million USD | 44.45% |
| 2010 | 1.93 Million USD | 49.11% |
| 2009 | 1.29 Million USD | 5.21% |
| 2008 | 1.23 Million USD | -22.98% |
| 2007 | 1.59 Million USD | 110.23% |
| 2006 | 760.46 Thousand USD | -0.5% |
| 2005 | 764.27 Thousand USD | -24.32% |
| 2004 | 1 Million USD | 17.03% |
| 2003 | 862.96 Thousand USD | 76.2% |
| 2002 | 489.77 Thousand USD | 4.6% |
| 2001 | 468.21 Thousand USD | -15.15% |
| 2000 | 551.78 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 4.71 Million USD | -34.14% |
| 2024 Q1 | 7.16 Million USD | -45.92% |
| 2023 Q1 | 4.09 Million USD | -2.8% |
| 2023 FY | 13.24 Million USD | 214.28% |
| 2023 Q2 | 4.64 Million USD | 13.31% |
| 2023 Q4 | 13.24 Million USD | 136.69% |
| 2023 Q3 | 5.59 Million USD | 20.56% |
| 2022 Q3 | 8.48 Million USD | -28.33% |
| 2022 Q4 | 4.21 Million USD | -50.34% |
| 2022 Q1 | 15.92 Million USD | -18.42% |
| 2022 FY | 4.21 Million USD | -78.41% |
| 2022 Q2 | 11.84 Million USD | -25.64% |
| 2021 Q1 | 18.14 Million USD | 27.86% |
| 2021 Q3 | 11.09 Million USD | -22.09% |
| 2021 Q4 | 19.52 Million USD | 75.92% |
| 2021 FY | 19.52 Million USD | 37.59% |
| 2021 Q2 | 14.24 Million USD | -21.49% |
| 2020 Q1 | 2.28 Million USD | -44.42% |
| 2020 FY | 14.18 Million USD | 244.94% |
| 2020 Q4 | 14.18 Million USD | 243.33% |
| 2020 Q3 | 4.13 Million USD | 82.67% |
| 2020 Q2 | 2.26 Million USD | -1.04% |
| 2019 FY | 4.11 Million USD | 40.97% |
| 2019 Q1 | 1.9 Million USD | -34.71% |
| 2019 Q2 | 7.59 Million USD | 298.45% |
| 2019 Q3 | 5.86 Million USD | -22.77% |
| 2019 Q4 | 4.11 Million USD | -29.84% |
| 2018 Q1 | 1.4 Million USD | -32.94% |
| 2018 FY | 2.91 Million USD | 39.7% |
| 2018 Q4 | 2.91 Million USD | 55.95% |
| 2018 Q3 | 1.87 Million USD | -18.38% |
| 2018 Q2 | 2.29 Million USD | 63.66% |
| 2017 FY | 2.08 Million USD | 11.78% |
| 2017 Q4 | 2.08 Million USD | -3.74% |
| 2017 Q3 | 2.16 Million USD | -1.16% |
| 2017 Q2 | 2.19 Million USD | -18.02% |
| 2017 Q1 | 2.67 Million USD | 43.3% |
| 2016 Q4 | 1.86 Million USD | -42.22% |
| 2016 Q1 | 4.03 Million USD | -15.28% |
| 2016 Q2 | 4.97 Million USD | 23.35% |
| 2016 Q3 | 3.23 Million USD | -34.95% |
| 2016 FY | 1.86 Million USD | -60.72% |
| 2015 Q4 | 4.75 Million USD | -18.55% |
| 2015 Q1 | 4.9 Million USD | -7.19% |
| 2015 Q2 | 4.48 Million USD | -8.51% |
| 2015 FY | 4.75 Million USD | -9.99% |
| 2015 Q3 | 5.84 Million USD | 30.14% |
| 2014 Q2 | 4.05 Million USD | 20.49% |
| 2014 FY | 5.28 Million USD | 89.47% |
| 2014 Q3 | 5.61 Million USD | 38.69% |
| 2014 Q4 | 5.28 Million USD | -5.93% |
| 2014 Q1 | 3.36 Million USD | 20.53% |
| 2013 Q2 | 2.95 Million USD | 5.51% |
| 2013 Q3 | 2.84 Million USD | -3.69% |
| 2013 Q4 | 2.78 Million USD | -1.89% |
| 2013 FY | 2.78 Million USD | 6.54% |
| 2013 Q1 | 2.79 Million USD | 6.86% |
| 2012 Q4 | 2.61 Million USD | -1.82% |
| 2012 Q1 | 2.82 Million USD | 1.19% |
| 2012 Q2 | 2.71 Million USD | -3.94% |
| 2012 FY | 2.61 Million USD | -6.17% |
| 2012 Q3 | 2.66 Million USD | -1.68% |
| 2011 Q4 | 2.79 Million USD | 10.95% |
| 2011 Q3 | 2.51 Million USD | 5.43% |
| 2011 Q1 | 2.26 Million USD | 17.11% |
| 2011 Q2 | 2.38 Million USD | 5.44% |
| 2011 FY | 2.79 Million USD | 44.45% |
| 2010 FY | 1.93 Million USD | 49.11% |
| 2010 Q2 | 1.37 Million USD | 3.71% |
| 2010 Q4 | 1.93 Million USD | 6.12% |
| 2010 Q3 | 1.82 Million USD | 32.69% |
| 2010 Q1 | 1.32 Million USD | 2.11% |
| 2009 Q2 | 1.25 Million USD | 0.44% |
| 2009 Q4 | 1.29 Million USD | -0.89% |
| 2009 FY | 1.29 Million USD | 5.21% |
| 2009 Q1 | 1.24 Million USD | 1.26% |
| 2009 Q3 | 1.3 Million USD | 4.37% |
| 2008 FY | 1.23 Million USD | -22.98% |
| 2008 Q4 | 1.23 Million USD | -19.16% |
| 2008 Q3 | 1.52 Million USD | 6.26% |
| 2008 Q2 | 1.43 Million USD | -1.95% |
| 2008 Q1 | 1.46 Million USD | -8.57% |
| 2007 Q2 | 861.3 Thousand USD | 10.22% |
| 2007 Q1 | 781.43 Thousand USD | 2.76% |
| 2007 Q4 | 1.59 Million USD | 61.96% |
| 2007 FY | 1.59 Million USD | 110.23% |
| 2007 Q3 | 987.09 Thousand USD | 14.61% |
| 2006 Q4 | 760.46 Thousand USD | 0.92% |
| 2006 FY | 760.46 Thousand USD | -0.5% |
| 2006 Q3 | 753.49 Thousand USD | -3.78% |
| 2006 Q2 | 783.13 Thousand USD | -7.35% |
| 2006 Q1 | 845.24 Thousand USD | 10.59% |
| 2005 FY | 764.27 Thousand USD | -24.32% |
| 2005 Q4 | 764.27 Thousand USD | -28.4% |
| 2005 Q1 | 1.05 Million USD | 4.94% |
| 2005 Q2 | 1.04 Million USD | -1.66% |
| 2005 Q3 | 1.06 Million USD | 2.43% |
| 2004 Q1 | 917.54 Thousand USD | 6.32% |
| 2004 Q3 | 991.49 Thousand USD | 3.44% |
| 2004 Q2 | 958.53 Thousand USD | 4.47% |
| 2004 FY | 1 Million USD | 17.03% |
| 2004 Q4 | 1 Million USD | 1.86% |
| 2003 Q4 | 862.96 Thousand USD | 63.44% |
| 2003 FY | 862.96 Thousand USD | 76.2% |
| 2003 Q1 | 476 Thousand USD | -2.81% |
| 2003 Q2 | 493.36 Thousand USD | 3.65% |
| 2003 Q3 | 527.99 Thousand USD | 7.02% |
| 2002 Q4 | 489.77 Thousand USD | -11.34% |
| 2002 Q1 | 501.39 Thousand USD | 7.09% |
| 2002 FY | 489.77 Thousand USD | 4.6% |
| 2002 Q2 | 523.47 Thousand USD | 4.4% |
| 2002 Q3 | 552.39 Thousand USD | 5.53% |
| 2001 Q4 | 468.21 Thousand USD | -3.58% |
| 2001 Q3 | 485.6 Thousand USD | -11.89% |
| 2001 FY | 468.21 Thousand USD | -15.15% |
| 2001 Q1 | 556.47 Thousand USD | 0.85% |
| 2001 Q2 | 551.12 Thousand USD | -0.96% |
| 2000 Q4 | 551.78 Thousand USD | -32.13% |
| 2000 Q3 | 812.94 Thousand USD | 0.0% |
| 2000 FY | 551.78 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | 80.017% |
| Safety Shot Inc | 12.7 Million USD | -4.236% |
| Bright Green Corporation | 17.4 Million USD | 23.878% |
| Embecta Corp. | 1.21 Billion USD | 98.909% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 98.535% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 76.928% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 98.841% |
| Dynavax Technologies Corporation | 997.09 Million USD | 98.671% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 93.563% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 98.181% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 99.159% |
| PainReform Ltd. | 9.93 Million USD | -33.409% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 51.558% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 51.558% |
| SCYNEXIS, Inc. | 128.41 Million USD | 89.684% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 42.718% |
| Journey Medical Corporation | 76.84 Million USD | 82.762% |
| Alpha Teknova, Inc. | 128.58 Million USD | 89.698% |
| Procaps Group, S.A. | 460.18 Million USD | 97.121% |
| Theratechnologies Inc. | 77.76 Million USD | 82.966% |
| Harrow Health, Inc. | 311.75 Million USD | 95.751% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | 11.049% |
| Biofrontera Inc. | 27.93 Million USD | 52.572% |
| DURECT Corporation | 45.18 Million USD | 70.684% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 99.06% |
| Cronos Group Inc. | 1.13 Billion USD | 98.832% |
| OptiNose, Inc. | 107.72 Million USD | 87.703% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 97.188% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 76.322% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 42.52% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 97.12% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -11.154% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 83.8% |
| Radius Health, Inc. | 1.71 Billion USD | 99.228% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 75.139% |
| ProPhase Labs, Inc. | 91.92 Million USD | 85.589% |
| Phibro Animal Health Corporation | 982.18 Million USD | 98.651% |
| Procaps Group S.A. | 460.18 Million USD | 97.121% |
| Alvotech | 950.09 Million USD | 98.606% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 69.412% |
| Viatris Inc. | 47.68 Billion USD | 99.972% |
| Rockwell Medical, Inc. | 52.17 Million USD | 74.608% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 88.782% |
| SIGA Technologies, Inc. | 254.83 Million USD | 94.802% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.694% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 95.16% |
| Shineco, Inc. | 84.17 Million USD | 84.263% |
| PetIQ, Inc. | 868.22 Million USD | 98.474% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -56.995% |
| Incannex Healthcare Limited | 17.04 Million USD | 22.288% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.593% |
| Alimera Sciences, Inc. | 153.52 Million USD | 91.371% |
| Silver Spike Investment Corp. | 88.57 Million USD | 85.044% |
| Assertio Holdings, Inc. | 286.41 Million USD | 95.375% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -122.583% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 60.801% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 57.598% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 94.927% |
| Hempacco Co., Inc. | 18.04 Million USD | 26.578% |
| Talphera, Inc. | 20.39 Million USD | 35.045% |
| Alvotech | 950.09 Million USD | 98.606% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 96.738% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 99.198% |
| Currenc Group, Inc. | 141.49 Million USD | 90.637% |
| Kamada Ltd. | 351.96 Million USD | 96.236% |
| Indivior PLC | 1.95 Billion USD | 99.321% |
| Evoke Pharma, Inc. | 7.06 Million USD | -87.415% |
| Flora Growth Corp. | 23.62 Million USD | 43.928% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | 0.0% |
| Evolus, Inc. | 188.99 Million USD | 92.991% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 98.965% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 99.124% |
| Akanda Corp. | 8.83 Million USD | -49.859% |